Dory A Sample1,2, Hoon H Sunwoo3, Hien Q Huynh4, Heather L Rylance5, Cheri L Robert5, Bi-Wen Xu1, Sung H Kang5, Naiyana Gujral1, Levinus A Dieleman6. 1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 3-142H Katz Centre for Pharmacy and Health Research, 11361-87 Ave, Edmonton, AB, T6G 2E1, Canada. 2. Women and Children's Health Research Institute, University of Alberta, 4-501 Edmonton Clinic Health Academy, 11405-87 Ave, Edmonton, AB, T6G 1C9, Canada. 3. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 3-142H Katz Centre for Pharmacy and Health Research, 11361-87 Ave, Edmonton, AB, T6G 2E1, Canada. hsunwoo@ualberta.ca. 4. Division of Pediatric GI Nutrition, Faculty of Medicine, University of Alberta, 4-579 Edmonton Clinic Health Academy, 11405-87 Ave, Edmonton, AB, T6G 1C9, Canada. 5. Women and Children's Health Research Institute, University of Alberta, 4-081 Edmonton Clinic Health Academy, 11405-87 Ave, Edmonton, AB, T6G 1C9, Canada. 6. Division of Gastroenterology, Faculty of Medicine, University of Alberta, Zeidler Bld 2-24, 130 University Campus, Edmonton, AB, T6G 2X8, Canada.
Abstract
BACKGROUND: Celiac disease (CD) is a gluten-triggered autoimmune disorder of the small intestine. A lifelong gluten-free diet (GFD) is the only approved treatment; however, strict adherence is difficult and many suffer from inadvertent gluten exposure. Oral egg yolk anti-gliadin antibody (AGY) is a novel treatment to neutralize gluten and may improve the efficacy of the GFD. AIMS: To determine the safety, tolerability, and potential efficacy of AGY in patients with CD. METHODS: This 6-week, open-label, single-arm study was conducted in adults with biopsy-proven CD on a GFD. Safety measures included adverse events, physical examination, and clinical laboratory tests. Additional measures included a daily Celiac Symptom Index, Health-Related Quality of life, anti-tissue transglutaminase and anti-gliadin IgA/IgG, and lactulose/mannitol excretion ratio (LMER). A 2-week run-in period to assess questionnaire compliance and acceptability of baseline safety laboratory results was followed by a 4-week treatment period with two AGY capsules taken before meals. RESULTS: Ten patients completed the study (mean age 43.4 years, nine female). All followed a GFD for at least 6 months (mean 5 years). No safety concerns were identified. Most patients had fewer celiac symptoms (especially tiredness, headache, and bloating), improved quality of life, lowered antibodies, and lowered LMER when taking AGY compared to the run-in period. CONCLUSION: In our cohort, AGY was safe and potentially associated with improved CD-related outcome measures in patients on a GFD. A larger study powered for further safety and efficacy evaluation is planned.
BACKGROUND:Celiac disease (CD) is a gluten-triggered autoimmune disorder of the small intestine. A lifelong gluten-free diet (GFD) is the only approved treatment; however, strict adherence is difficult and many suffer from inadvertent gluten exposure. Oral egg yolk anti-gliadin antibody (AGY) is a novel treatment to neutralize gluten and may improve the efficacy of the GFD. AIMS: To determine the safety, tolerability, and potential efficacy of AGY in patients with CD. METHODS: This 6-week, open-label, single-arm study was conducted in adults with biopsy-proven CD on a GFD. Safety measures included adverse events, physical examination, and clinical laboratory tests. Additional measures included a daily Celiac Symptom Index, Health-Related Quality of life, anti-tissue transglutaminase and anti-gliadin IgA/IgG, and lactulose/mannitol excretion ratio (LMER). A 2-week run-in period to assess questionnaire compliance and acceptability of baseline safety laboratory results was followed by a 4-week treatment period with two AGY capsules taken before meals. RESULTS: Ten patients completed the study (mean age 43.4 years, nine female). All followed a GFD for at least 6 months (mean 5 years). No safety concerns were identified. Most patients had fewer celiac symptoms (especially tiredness, headache, and bloating), improved quality of life, lowered antibodies, and lowered LMER when taking AGY compared to the run-in period. CONCLUSION: In our cohort, AGY was safe and potentially associated with improved CD-related outcome measures in patients on a GFD. A larger study powered for further safety and efficacy evaluation is planned.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jason A Tye-Din; Robert P Anderson; Rosemary A Ffrench; Gregor J Brown; Peter Hodsman; Matthew Siegel; Wendy Botwick; Revati Shreeniwas Journal: Clin Immunol Date: 2009-11-25 Impact factor: 3.969
Authors: Mirco Vacca; Annalisa Porrelli; Francesco Maria Calabrese; Tamara Lippolis; Ilaria Iacobellis; Giuseppe Celano; Daniela Pinto; Francesco Russo; Gianluigi Giannelli; Maria De Angelis Journal: Front Microbiol Date: 2022-06-23 Impact factor: 6.064
Authors: Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors Journal: Nat Rev Gastroenterol Hepatol Date: 2020-11-20 Impact factor: 46.802